Services

1. API Process Development 6/1/2012

   Cedarburg Hauser Pharmaceuticals now has the technology and experience to offer you synthetic and semi-synthetic process development as well as natural product isolation and purification.

2. Clinical Storage 6/24/2011
   CSM® has expertise in global distribution to the European Union (EU), depots and other international distribution service providers, and ensures seamless shipping and customs release of clinical supplies to virtually every continent.
3. Pharmaceutical Development 4/24/2023

   Developing an optimized formulation tailored to your API nanoparticles is critical to unlocking their full potential.

4. cGMP Aseptic Manufacturing And Sterile Fill-Finish 1/28/2022

   Experienced CDMOs will implement a cGMP aseptic manufacturing and sterile fill-finish policy to improve drug bioavailability. Aseptic fill-finish is a process in which the drug product, container, and container closure are sterilized separately and then integrated. Combining the drug, container, and closure in a clean room using special equipment that is self-contained in a sterile environment meets FDA guidelines related to cGMP.

5. Formulations For Poorly Soluble And Low Bioavailability Drugs 1/28/2022

   Ascendia specializes in the development of market suitable formulations for poorly water soluble drug substances. Based on the pre-formulation data package and the delivery requirements for the product, we recommend a comprehensive formulation development strategy. We understand that each formulation is unique and must address the specific challenges associated with poor solubility, inadequate bioavailability, and/or unacceptable physical/chemical stability. We also understand the urgency companies have for progressing their pipeline, and our approach maximizes the probability of success by exploring multiple formulation options in parallel if necessary.

6. Clinical Manufacturing In Viral Vaccines 4/14/2014

   Charles River offers more than 20 years of experience in manufacturing viral vaccines.

7. Fill & Finish / Late-Phase And Commercial Pharmaceutical Manufacturing 1/28/2014

   OsoBio is committed to serving as your contract manufacturing organization (CMO) of choice for late-phase clinical trials and bringing them to commercialization – especially those that involve biologic, highly potent or controlled compounds.

8. Lyophilization / Late-Phase And Commercial Pharmaceutical Manufacturing 1/28/2014

   OsoBio is committed to serving as your contract manufacturing organization (CMO) of choice for late-phase clinical trials and bringing them to commercialization – especially those that involve biologic, highly potent or controlled compounds.

9. Fill & Finish / Potent And Cytotoxic Compounds 1/28/2014

   As a first adopter of new international cross-containment guidelines recommended by ISPE (Risk-MaPP), OsoBio expertly manages the risks posed by potent and cytotoxic compounds and DEA scheduled substances, successfully balancing the need for product quality and operator safety.

10. Lyophilization / Potent And Cytotoxic Compounds 1/28/2014

    As a first adopter of new international cross-containment guidelines recommended by ISPE (Risk-MaPP), OsoBio expertly manages the risks posed by potent and cytotoxic compounds and DEA scheduled substances, successfully balancing the need for product quality and operator safety.